|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF V600E mutations occur frequently in malignant melanoma, but are rare in most malignant glioma subtypes.
|
29039591 |
2017 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Conclusions Cobimetinib is generally well tolerated and durable responses were observed in BRAF(V600E) mutant melanoma patients.
|
27424159 |
2016 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Compared with intravenous dacarbazine, vemurafenib significantly improved overall survival and progression-free survival in patients with unresectable, previously untreated, BRAF(V600E) mutation-positive, stage IIIC or IV melanoma.
|
23329082 |
2013 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
|
27690220 |
2016 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
B-RAF mutations, predominantly the specific V600E mutation and additional alterations in exons 11 and 15, were frequently detected in malignant melanomas, papillary thyroid tumors, and colorectal cancers with microsatellite instability (MSI).
|
16413100 |
2006 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
With regard to the frequency of V599E BRAF mutations, AM significantly differs from CM (P < or = .0001), which suggests that BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level.
|
15578519 |
2004 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF inhibitors target the BRAF-V600E/K mutated kinase, the driver mutation found in 50% of cutaneous melanoma.
|
30429474 |
2018 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
|
24670642 |
2014 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Gossypol retained its efficacy in BRAF-V600E melanoma clones with acquired resistance to BRAF inhibitors through a mechanism independent of MEK-ERK inhibition.
|
24625733 |
2014 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
B-RAF mutations were detected in cell lines OCM-1 and -3 (V600E) and in six primary uveal melanomas.
|
18172070 |
2008 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Patients diagnosed with BRAF V600E mutated cutaneous melanoma show response to treatment with the BRAF inhibitor Vemurafenib.
|
23159593 |
2013 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
|
27666765 |
2017 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Two patients with BRAF-V600E mutant melanoma who had documented progression during treatment with dabrafenib/GSK1120212 and dabrafenib, respectively, were rechallenged with dabrafenib and vemurafenib after a treatment-free interval of 8 and 4 months during which further progression was documented.
|
22584957 |
2012 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We established vemurafenib-resistant (VR) cells from three BRAF (V600E)-mutated melanoma lines (C32, HMY-1, and SK-MEL-28) and evaluated the mechanism of acquired resistance of VR cells by water-soluble tetrazolium salts assay, western blot, real-time quantitative PCR, and immunofluorescent microscopy.
|
30920401 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Genetic characterization of a predominant V600E mutation in melanoma, thyroid cancer, and other tumors became a focus for developing specific inhibitors, such as vemurafenib or dabrafenib.
|
24495477 |
2015 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation may be associated with an unfavorable prognosis among melanoma patients.
|
25048604 |
2014 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The V600E mutation of BRAF (BRAF<sup>V600E</sup>), which constitutively activates the ERK/MAPK signaling pathway, is frequently found in melanoma and other cancers.
|
31548614 |
2020 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We conclude that PRIMA-1(Met) through its ability to directly reactivate p53 regardless of the mechanism causing its deactivation, and thereby dampen PI3K signalling, sensitises (V600E/K)BRAF-positive melanoma to BRAF inhibitors.
|
26790143 |
2016 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The development of RAF inhibitors targeted against BRAF V600E mutant melanoma cells has revolutionized the treatment of MM.
|
23174497 |
2012 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
RAF is among the most frequently mutated kinases, where BRAF V600E mutation occurs in most hairy cell leukemias (HCL) and half of malignant melanomas.
|
25034364 |
2014 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF inhibitors (BRAFi) are used to treat patients with melanoma harboring the V600E mutation.
|
30482853 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
This study evaluated the safety and tolerability, pharmacokinetics (PK) and preliminary efficacy of dabrafenib 150 mg b.i.d. plus trametinib 2 mg q.d. in Japanese patients with BRAF V600E/K mutant solid tumors (phase 1) and melanoma (phase 2).
|
29399853 |
2018 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
CTC profiling was performed using 5 known melanoma mRNA biomarkers and BRAF V600E DNA mutation.
|
31672856 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Primary pineal malignant melanoma with B-Raf V600E mutation: a case report and brief review of the literature.
|
25976339 |
2015 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 additional patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.
|
20818844 |
2010 |